Vertex Pharmaceuticals Change In Cash Over Time
| VRTX Stock | USD 468.13 3.57 0.77% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vertex Pharmaceuticals Performance and Vertex Pharmaceuticals Correlation. Vertex |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.01 | Earnings Share (1.92) | Revenue Per Share 41.185 | Quarterly Revenue Growth 0.116 | Return On Assets 0.1205 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Cash Analysis
Compare Vertex Pharmaceuticals and related stocks such as Biomarin Pharmaceutical, Sarepta Therapeutics, and Seagen Inc Change In Cash Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMRN | 3.4 M | (41.8 M) | 134.3 M | 388.3 M | 306.7 M | (478.4 M) | 11.3 M | 189.7 M | (104 M) | (56.5 M) | 211.7 M | (61.9 M) | 137.3 M | 30.6 M | 31.7 M |
| SRPT | (1.2 M) | 6.3 M | 147.8 M | 69.3 M | (183.4 M) | 6.8 M | 42.1 M | 477.3 M | (229 M) | 472.8 M | 668.1 M | 613.8 M | (1.1 B) | (541.8 M) | (514.7 M) |
| ALNY | 17.3 M | (4.4 M) | (18.8 M) | 1.8 M | 22 M | 105.7 M | 12.7 M | 451.7 M | (224.2 M) | 127 M | (50.6 M) | 323.1 M | 46.4 M | (53.7 M) | (51 M) |
| NTLA | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 66 M | 197.2 M | 67.6 M | (281.8 M) | (1.6 M) | 107.4 M | (39.1 M) | 410 M | (295.1 M) | (280.4 M) |
| EDIT | 6 M | 6 M | 6 M | 6 M | 8.6 M | 132.6 M | 42.1 M | (38.7 M) | (11.9 M) | 103.4 M | (96.2 M) | 63.8 M | (62 M) | (17.9 M) | (17 M) |
| BEAM | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 146 M | (97.4 M) | 126.5 M | 395.7 M | (327.2 M) | 199.1 M | 209 M |
| DNA | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | (112.6 M) | 1.2 B | (223.3 M) | (380 M) | (361 M) |
| BNTX | (131.6 M) | (131.6 M) | (131.6 M) | (131.6 M) | (131.6 M) | (131.6 M) | (131.6 M) | (131.6 M) | 239.4 M | 107.7 M | 691.1 M | 482.5 M | 12.2 B | (2.2 B) | (2.1 B) |
| MRNA | 915 K | 915 K | 915 K | 915 K | 915 K | 261.8 K | (109 M) | 84.8 M | 523.5 M | (422.8 M) | 2.4 B | 4.2 B | (3.6 B) | (289 M) | (274.6 M) |
| REGN | 7.1 M | 371 M | (253.3 M) | 305.3 M | 113.1 M | 160.4 M | (273.9 M) | 277.5 M | 655 M | 150.1 M | 577 M | 690.8 M | 221.3 M | (381.6 M) | (362.5 M) |
| VKTX | 179.6 K | 179.6 K | 179.6 K | 179.6 K | 576.2 K | 12.7 K | 2.3 M | 5.9 M | 15.8 M | (16.4 M) | 20.7 M | (2.7 M) | 10.3 M | 18.9 M | 19.8 M |
| PTCT | (243.5 K) | (243.5 K) | (25.7 M) | 12.7 M | 34.3 M | 8.3 M | 299 K | 53.5 M | 57.7 M | 126 M | (79.2 M) | (19.1 M) | 98.7 M | 314.4 M | 330.1 M |
| KRYS | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 47.7 M | 54.1 M | 83.8 M | 80.8 M | 73 M | (179.3 M) | 196.4 M | 206.2 M |
| MDGL | 7.1 M | (1.2 M) | 51.4 M | (33 M) | (2.5 M) | (11.1 M) | 18.8 M | 129.5 M | (91.2 M) | (10.7 M) | 7.3 M | (17.7 M) | 295.3 M | (231.6 M) | (220.1 M) |
| CRSP | 584 K | 584 K | 584 K | 584 K | 584 K | 155 M | 159.6 M | (75.8 M) | 216.9 M | 489 M | 236.7 M | (245.5 M) | (715.9 M) | 177 M | 185.9 M |
| CRBU | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (25.1 M) | 224.5 M | (182.1 M) | (7.2 M) | (6.8 M) |
| VERV | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | 6.2 M | 60.1 M | 50.7 M | 90.7 M | 95.3 M |
Vertex Pharmaceuticals and related stocks such as Biomarin Pharmaceutical, Sarepta Therapeutics, and Seagen Inc Change In Cash description
My Equities
My Current Equities and Potential Positions
| Vertex Pharmaceuticals | VRTX |
| Classification | Pharmaceutical Products |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 468.13
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.